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SUMMARY  
Our analysis of TB prevalence surveys showed that a median of 50.4% of prevalent bacteriologically-
confirmed TB was subclinical, i.e.  negative on symptom screening. Chest X-ray detected 89% of 
cases. This could potentially suggest a change in TB case-finding policies.    
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ABSTRACT  
While it is known that a substantial proportion of individuals with tuberculosis disease (TB) present 
subclinically, usually defined as bacteriologically-confirmed but negative on symptom screening, 
considerable knowledge gaps remain. Our aim was to review data from TB prevalence population 
surveys and generate a consistent definition and framework for subclinical TB, thus enabling an 
estimate of the proportion of TB that is subclinical, explore associations with overall burden and 
programme indicators, and performance of screening strategies. We extracted data from all publicly 
available prevalence surveys conducted since 1990. Between 36.1–79.7% (median 50.4%) of 
prevalent bacteriologically-confirmed TB was subclinical. No association was found between 
prevalence of subclinical and all bacteriologically confirmed TB, patient diagnostic rate or country-
level HIV prevalence (p-values, 0.32, 0.4, 0.34, respectively). Chest X-ray detected 89% (range 73–
98%) of bacteriologically-confirmed TB disease, highlighting the potential of optimizing current TB 
case-finding policies.    
 
KEY WORDS 
Subclinical TB; TB screening; TB prevalence surveys; Symptom screening; Chest X-ray screening. 
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MEETINGS WHEREIN THE INFORMATION HAS PREVIOUSLY BEEN PRESENTED 
An early version of this analysis was presented at the 50th Union World Conference on Lung Health in 
Hyderabad, India, October 30th – November 2nd 2019.  
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BACKGROUND  
 
Tuberculosis disease (TB) remains the leading cause of death from an infectious disease in the 
world[1]. Not all individuals with bacteriologically-confirmed TB will present with, or be aware of 
(clinical) symptoms [2]. When presenting to TB services, this asymptomatic yet infectious group is 
usually missed, as access to care mostly relies on positive symptom screening to start the TB 
diagnostic pathway[3]. Individuals with so-called subclinical TB could therefore continue to 
contribute to transmission[4], hindering global TB care and prevention efforts [1]. 
 
While the importance of the subclinical TB subpopulation is recognized, a clear definition has not 
been agreed upon. Both “asymptomatic” and “bacteriologically-confirmed” are inherently 
ambiguous. The extent and duration of symptoms used for screening will change the proportion of 
cases that have a positive symptom screening [5]. Similarly, the extent of bacteriological 
examination, e.g. the number of samples or technique used, will change the proportion that will be 
bacteriologically confirmed [6][7].  
 
To enable progress, we propose to define asymptomatic and bacteriologically-confirmed TB as 
defined by TB prevalence surveys, which are population-based surveys that investigate 
representative samples of the population to estimate the national prevalence of bacteriologically-
confirmed adult pulmonary TB. Through X-ray and symptom screening, individuals become eligible 
for sputum investigation with Xpert and/or culture (Table 1)  [8]. While some variation remains, 
prevalence surveys can provide comparable measurements for the majority of high-burden 
countries [9], both between and within countries over time for the proportion of TB that is 
subclinical, i.e. asymptomatic (usually defined as negative on screening for cough of a certain 
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duration) and bacteriologically-confirmed (usually defined as positive on at least one culture or PCR-
based test). Through this definition, subclinical TB can be placed in a comprehensive framework that 
reflects the relevant stages and flows in the spectrum of TB infection and disease.  
 
Our aim was to review data from TB prevalence population surveys and generate a consistent 
definition and framework for subclinical TB, thereby enabling us to estimate of the proportion of TB 
that is subclinical as well as explore associations with overall burden and programme indicators. 
Finally, we considered the potential performance of chest X-ray based screening strategies to 
replace the current symptom-focused TB care and prevention policies. 
 
METHODS  
 
We considered for inclusion population-based TB prevalence surveys completed from 1990, with 
reports or papers publicly available by August 2019. A literature search for the period from January 
1990 to August 2019, restricted to the English language, was conducted by one author (I.L.) in 
PubMed (August 2019) using the following search terms: “tuberculosis” and “prevalence” in the title 
and “survey” as text words. Reference lists of identified studies were also examined. Studies that 
were about a subset of TB cases (e.g. drug-resistant TB, women only, health care workers), TB 
infection rather than TB disease and risk factors for TB (e.g. diabetes), and review articles were 
excluded. Grey literature, such as unpublished survey reports produced by national TB programmes, 
abstracts and presentations from international meetings, and routine progress updates collated by 
the WHO Global Task Force on TB Impact Measurement on the status of surveys since 2008, was also 
systematically reviewed. 
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Subnational TB prevalence surveys were included from the review by Horton et al [10]. Surveys were 
included if both symptom screening interview and X-ray were performed on all eligible participants, 
and surveys reported the proportion of bacteriologically-confirmed cases by screening modality as 
well as the proportion of bacteriologically-confirmed cases that were negative on symptom 
screening. 
 
We extracted data on the burden of TB (prevalence of bacteriologically-confirmed TB), screening and 
bacteriological confirmation methods, outcomes of screening of the study population, and outcomes 
of screening of bacteriologically-confirmed cases. To explore the impact of programme performance, 
we generated the patient diagnostic rate (PDR), as the case notification rate (number of individuals 
diagnosed with TB disease and reported to the National TB Programme, per 100,000 population), 
divided by the prevalence of bacteriologically-confirmed TB [10] (inverse of the prevalence to 
notification ratio). 
 
We defined subclinical TB cases as all participants who were negative on symptom screening, 
following the criteria established in each survey, but confirmed on bacteriological testing. A 
framework for the natural history of TB was then developed to place subclinical disease in the 
spectrum of Mycobacterium tuberculosis infection and TB disease.  
 
Bacteriological confirmation generally included at least one positive culture or PCR-based test [8]. 
Participants not eligible for X-ray screening (e.g. because of pregnancy) were considered negative at 
X-ray screening. 
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In settings where TB prevalence surveys were repeated in the same geographical area using similar 
methodology, we examined longitudinal trends in subclinical TB.  
We performed a meta-regression (metareg in STATA v15) analysis for the effect of covariates on the 
proportion of subclinical TB. To avoid interdependency, one survey per country or area was 
included. We explored the association with TB prevalence in country, continent, country-level HIV 
prevalence, definition of symptom screen, the PDR as a metric of programme performance, and 
proportion of cases that was male. We also performed a random-effects meta-analysis, using the 
metaprop command in STATA v15 [11], to quantify between study heterogeneity. 
 
To examine the relative contribution of symptoms compared to X-ray as a screening tool, we 
analyzed the proportion of bacteriologically-confirmed cases identified through each method. We 
also analyzed the proportion of participants that screened positive via symptoms interview, on X-ray, 
or on both methods, and were considered eligible for bacteriological examination. 
 
RESULTS 
We included 23 national surveys and 5 subnational surveys, conducted in 23 countries across Africa 
and Asia, representing 36% of the global TB burden in 2018[1], and 57.5% (23/40) of all national 
level surveys completed since 1990 (Data available in Tables 1-3, List of references for included 
surveys available in Supplementary Material as Appendix 1). The reasons for exclusion of the 
remaining prevalence surveys are available in Figure 1. 
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The 2013 Malawi survey was excluded because of reported issues in the quality of X-ray in many 
clusters [12]. Surveys from China were excluded because results were only reported for smear-
positive or ‘active pulmonary cases’, the latter including an unknown proportion of bacteriologically 
negative, clinically diagnosed cases, which did not match our criteria [13]. Data from these surveys 
are included in Tables 1-3.   
 
Across included surveys, the median percentage of subclinical TB cases was 50.4% (Interquartile 
range (IQR) 39.8–62.3%, range 36.1–79.7%), which was 49.4% (IQR 38.8–52.4%) in African countries, 
while in the Asian countries the median was 56.4% (IQR 42.8–68.5%), with no discernable trend by 
TB prevalence (Figure 2) in either continent.  
 
Data on repeated surveys were available from Cambodia and Tamil Nadu state in India, although no 
clear trend is present, they seemed to suggest that the proportion of subclinical TB increased as TB 
prevalence declined (Tables 2-3). An indication for this trend was also seen among smear-positive TB 
in surveys repeated in China from 2000 and 2010 (Table 3).  
 
As Figure 3 shows, X-ray screening identified the vast majority of bacteriologically-confirmed cases in 
all countries (median=89%, range 73–98%). In contrast, the percentage of bacteriologically-
confirmed TB cases that were negative on X-ray but positive on symptom was below 25% (median 
7%, range 0.7– 22%) in all surveys, with between 0.01 and 15% of bacteriologically-confirmed cases 
diagnosed through direct bacteriological examination (see Figure 3 or Table 1).   
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In the sampled population, surveys found that 8.8% of individuals screened positive on X-ray (range 
4.8-26%), whereas 6.3% (range 3–21%) were positive on symptoms (Figure 3).  
 
We frame subclinical pulmonary TB in the wider context of TB natural history in Figure 5. Here, 
subclinical TB is a distinct intermediary disease state, which follows after a minimal disease state 
with initial pathological changes (e.g. visible on imaging), but not bacteriologically confirmed (at 
least within the limits of sampling undertaken) and unlikely to be contributing to transmission. 
Crucially, individuals can progress and regress from each stage, although how fast or frequent 
individuals move between stage will vary widely [14][15].   
 
Table 4 shows the results from the meta-regression, which provided evidence that in our sample, 
the proportion of subclinical TB cases was higher in surveys from Asia compared to those from Africa 
(15.2%, 95% CI (5.6 – 24.8)). There was no evidence for an association with any of the other 
variables, including country-level TB or HIV prevalence, symptom-screen algorithm or PDR. Results 
from the meta-analysis showed very high heterogeneity (I2 = 96%, p-value<0.001). The forest plot is 
shown in Appendix 2 of Supplementary Material. 
DISCUSSION  
Where measured, around half of the prevalent infectious TB disease burden is subclinical, making it 
likely that ignoring this burden will diminish the impact of TB care and prevention efforts.  
Our results show that cough, the cornerstone of symptom-based screening policies, was only self-
reported by around half of bacteriologically-confirmed cases in populations across Asia and Africa. 
Expecting extensive population-level impact on transmission from such policies seems misplaced. 
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Similar to historical observations that a large bacillary load is not required for transmission [16][17], 
cough is unlikely to be required for transmission[18], 
 
We found that nine out of ten individuals with bacteriologically-confirmed TB, including those with 
subclinical disease, were positive on X-ray-based screening, which is based on a single posterior 
anterior image. We would therefore argue that X-ray as a clinical screening tool needs a re-
evaluation as part of the End TB Strategy. Aside from its ability to detect the majority of infectious 
TB, rapid advancements in digitalization, portability of X-ray screening and computer aided X-ray 
reading now enable clear and consistent choices, which can be adjusted to fit the context of each 
country to further enhance performance [19].  It is now possible to strike a reproducible balance 
between the need to increase the proportion of all infectious TB disease found (sensitivity) and the 
proportion of screened individuals that are referred for bacteriological testing (positivity rate) [19], 
the latter of which varied between 7.1% to 24% in surveys included in our analysis. As such, the X-ray 
screening can be optimized depending on the population screened, whether these are clinic 
attendees or community-based.  
 
Prevalence surveys do not capture individuals with symptom-negative, X-ray negative, 
bacteriologically-confirmed TB. While the data is limited, it suggests that another 0-5% of all 
bacteriologically-confirmed TB would be classified as subclinical [20], which means our estimates for 
subclinical TB would be conservative. In addition, pediatric and extrapulmonary TB are not measured 
in prevalence surveys.  
 
Our results are limited to 36% of the global TB burden, and therefore key gaps remain, including 
China (where surveys have not reported details for bacteriologically-confirmed TB cases), India and 
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South Africa (surveys underway). We strongly argue that surveys should report results separately by 
screening and bacteriological confirmation, and data could be enriched, for example with further 
subdivisions by gender, urban or rural strata, and HIV status to help inform strategies to address this 
burden. In addition. Our data reflect the proportion that is subclinical amongst the prevalent burden 
of the infectious disease, not incident disease. In addition, our study does not include data from low 
TB incidence settings. 
 
In particular, increased trends over time in the size and composition of the subclinical TB population 
as the overall TB prevalence changes would improve our understanding of population dynamics. 
Maximizing the number of repeat data points within countries would enable a within-country 
analysis of the impact of programme performance, including their (limited) ability to address 
subclinical TB. Our ecological analysis found no association between programme performance and 
subclinical TB, likely due to unmeasured confounding factors specific to each setting. Improved 
reporting would also provide more data points, which may increase power for more subtle analyses, 
such as the proportion of subclinical TB by duration of cough, sex, or differences between 
continents.  
 
We would caution for overinterpretation of the evidence for a difference by continent from meta-
regression (Table 4) and meta-analysis (Appendix 2), especially given that only a subset of countries 
for each continent is included in our study. Unmeasured confounding factors include differences in 
the host genetics and bacillary strains which could affect the natural history of the disease[21]. In 
addition, not all surveys followed exactly same protocol, not all of which was captured in our 
analysis. Other possible factors are related to cultural differences regarding awareness of symptoms 
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and bacteriological confirmation criteria and techniques. Further studies are necessary to explore 
the causes and consequences of this result. 
 
Despite the limitations described above, prevalence surveys offer clear advantages as a framework 
for analysis. Firstly they represent the most consistent, valid and extensive effort for TB burden 
estimation of the past three decades [1] and aim to reflect in-country clinical practice and case 
definitions. As a consequence, we could address the persistent ambiguity of the definitions for 
subclinical TB, in particular the precise interpretation of ‘asymptomatic’ and ‘bacteriologically-
confirmed’.  
 
Our framework places subclinical TB as a distinct intermediary disease state, which precedes clinical 
(i.e. symptomatic) disease and follows after a minimal disease state. Moreover, incipient disease is 
not a stage, but, as indicated in the name, represents the flow from minimal to subclinical disease.  It 
must be noted that the prevalence of the minimal disease state might be influenced by the 
limitations of X-ray, and more sensitive imaging techniques, such as CT scan, would be more 
sensitive for initial pathological changes. Progression and regression across the TB natural history 
spectrum has been postulated, and is supported by historical and recent data. [22]. The term 
‘incipient TB’ has been widely used to refer to a group of individuals who will soon progress to 
subclinical disease. While this makes it an attractive diagnostic target for predictive tests [23][24], 
the word and concept of ‘incipient’ implies both a transition and direction, which is a flow, not be a 
disease state. 
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Our analysis and conceptual framework should enable scientific discourse and policy 
progress on the unaddressed burden of subclinical TB. A key consideration is how subclinical 
TB contributes to transmission, given that individuals do not report (prolonged) cough. 
However, people may not recognize cough as a symptom, and cough not be required for 
effective transmission[4]. A comparison of health seeking behavior between individuals with 
subclinical (asymptomatic) and clinical (symptomatic) disease could shed more light on the 
impact of recognizing symptoms on accessing care, but unfortunately prevalence surveys did 
not report the required stratified data. Another advantage is that these disease stages could 
help distinguish a sub-population of patients for whom shorter treatment is both beneficial 
and safe. [25] 
A significant proportion of the global TB burden is asymptomatic and not detectable by current 
symptom-based screening efforts, and fueling the TB epidemic through continued Mycobacterium 
tuberculosis transmission [4]. Detecting subclinical TB provides an opportunity to provide care early 
in the disease history, which should benefit individuals by preventing extensive lung damage and the 
risk of post-TB sequelae[26], and benefit society by interrupting transmission. There are both 
historical and recent precedents to support this thesis, showing that symptom-agnostic screening 
through X-ray[27] or Xpert[28]  has near immediate impact disease burden in high incidence 
settings. The TB community needs to recognize both the challenge and opportunities of subclinical 
TB and develop strategies to address it. If we do so, we should have a much better chance of ending 
TB in our lifetime. 
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Table 1. Prevalence of TB and characteristics of screening 
Survey 
Crude 
Prevalence 
of TB 
(95%CI) 
n/100 000 
population 
Estimated 
incidence 
(95% CI) 
n/100 000 
population 
Symptom 
screening 
criteria 
 X-ray 
screening 
device 
 X-ray screening 
criteria 
Bacteriological 
confirmation 
test 
Criteria for 
eligibility for 
bacteriological 
examination 
Total 
number of 
individuals 
screened 
Proportion 
of 
individuals 
screened  
that is  
S-X- 
(%) 
Proportion 
of 
individuals 
screened  
that is 
S+X- 
(%) 
Proportion 
of 
individuals 
screened  
that is 
S+X+ 
(%) 
Proportion 
of 
individuals 
screened  
that is  
S-X+ 
(%) 
Other 
(%) 
 
Bangladesh 
2015 
287 (244-
330) 
221 (160-
290) 
Symptom 
screening 
score ≥ 3 
Digital 
mobile X-ray 
Any lung 
abnormality 
consistent with TB 
Culture 
positive 
and/or Xpert 
positive 
S+ and/or X+ 
or XNA and 
symptom 
score ≥1  
98710 79.4 4.2 3.1 13.8 
S+XNA 
0.04 
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Cambodia 
2002 
1208 (992-
1463) 
600 
Cough ≥ 3 
weeks 
and/  or 
hemoptysis 
in the 
previous 
month 
Portable X-
ray machine 
TB related 
shadows (active, 
suspected and 
healed TB) or 
other lung 
disease, except for 
those with a single 
calcification 
nodule only or a 
minor pleural 
adhesion at the 
costophrenic 
angle 
Smear 
positive 
and/or culture 
positive 
S+ and/or X+ 
or XNA 
22160 
not 
reported 
4.6 2.6 8.2 
include 
XNA 
Cambodia 
2011 
831 (707-
977) 
Not 
reported 
Cough ≥ 2 
weeks 
and/  or 
hemoptysis 
Portable X-
ray machine 
Any abnormal 
shadow in the 
lung field or 
mediastinum 
other than a single 
small calcification 
nodule with a size 
less than 10 mm 
or pleural 
adhesion at 
costophrenic 
Smear 
positive 
and/or culture 
positive 
S+ and/or X+ 
or XNA 
37417 87.22 3.1 1.9 7.2 
S-XNA 0.4 
S+XNA 
0.1 
“Other” 
0.02 
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angle(s) 
China 
2000a 
466 
Not 
reported 
Cough ≥ 3 
weeks 
and/  or 
hemoptysis 
≥ 3 weeks 
Chest 
fluoroscopy 
to all 
subjects, 
then X-ray if 
they showed 
abnormal 
results 
Abnormal findings 
except hilar 
calcification, a few 
fibrotic indurated 
lesions, small area 
of pleural 
thickening 
  
S+ and/or X+ 
and all known 
TB cases 
365097 
Not 
reported 
Not 
reported 
Not 
reported 
Not 
reported 
Not 
applicable 
China 
2010a 
459 
Not 
reported 
Not 
reported 
Not reported Not reported 
Smear 
microscopy 
and culture 
S+ and/or X+ 
and all known 
TB cases 
252940 
Not 
reported 
Not 
reported 
Not 
reported 
Not 
reported 
Not 
applicable 
DPR Korea 
2016 
567 (510-
631) 
Not 
reported 
Cough ≥ 2 
weeks 
and/  or 
hemoptysis 
Portable X-
ray machine 
Abnormal chest 
radiograph in the 
lung field or 
mediastinum 
other than a single 
small calcification 
nodule with a size 
less than 10 mm 
or pleural 
adhesion at cost-
phrenic angle(s) 
Culture 
positive 
S+ and/or X+ 60683 
Not 
reported 
Not 
reported 
1.7 3.1 
S-X- or S-
XNA 92 
S+X- or 
S+XNA 
3.2 
Indonesia 759 (589- Not Cough ≥ 2 Digital Any lung or pleura Smear S+ and/or X+  67944 77.3 5.7 6.6 9.9 S+XNA 
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2014 961) reported weeks 
and/  or 
hemoptysis 
mobile X-ray abnormality positive 
and/or culture 
positive 
and/or Xpert 
positive 
or XNA 0.37 
S-XNA 
with any 
symptom 
of TB 0.2 
Lao PDR 
2011 
595(457-
733) 
Not 
reported 
Cough ≥ 2 
weeks 
and/  or 
hemoptysis 
in the 
previous 
month 
Full size 
conventional 
CXR 
Any abnormal 
lung field shadow 
Culture 
positive 
S+ and/or X+ 39212 83.8 
Not 
reported 
3.3 7.9 
S+X- or 
S+XNA 
4.9 
Mongolia 
2015 
559.6 
(454.5-
664.7) 
428 (220-
703) 
Cough ≥ 2 
weeks 
Digital 
mobile X-ray 
Any abnormal 
shadow in lung 
field and 
mediastinum or 
pleural effusion 
Smear 
positive 
and/or culture 
positive 
S+ and/or  X+  
or XNA 
50309 79.3 3.4 1.6 14 
S+XNA 
0.08 
SNA X+ 
0.06 
SNA XNA 
1.5 
Myanmar 
2009 
612.8 
(502.2-
747.6) 
526 (307-
802) 
Any 
symptom 
Portable X-
ray machine 
Any abnormality 
in the lung field or 
mediastinum 
greater than a 
single small 
calcification 
Smear 
positive 
and/or culture 
positive 
S+ and/or  X+  
or XNA 
51367 76.2 0.8 2.5 18.3 
S-XNA 2.1 
S+XNA 
0.1 
Suspected 
false 
negative 
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nodule or pleural 
adhesion at the 
costophrenic 
angle 
CXR 0.1 
Philippines 
2016 
1159 
(1016-
1301) 
554 (311-
866) 
Cough ≥ 2 
weeks 
and/  or 
hemoptysis 
in the 
previous 
month 
Mass 
miniature 
radiography 
Any abnormality 
suggestive of TB 
Culture 
positive 
and/or Xpert 
positive 
S+ and/or X+ 
or XNA 
46689 60.2 2.8 2.9 22.9 
S+XNA 
0.3 
S-XNA 
10.9 
Thailand 
2012c 
142 (166.3-
287.8) 
Not 
obtainable 
Cough ≥ 2 
weeks 
Not 
obtainable 
Not obtainable 
Smear 
positive 
and/or culture 
positive 
Not 
obtainable 
62536 90.3 2.8 0.8 6 
includes 
XNA 
Vietnam 
2007 
286 171 
Cough ≥ 2 
weeks 
Either mass 
miniature 
radiography 
or digital 
mobile X-ray 
Any abnormality 
suggestive of TB 
Smear 
positive 
and/or culture 
positive 
S+ and/or  X+  
or TB current 
treatment or 
history of 
treatment 
within 2 years 
94179 92.2 0.01 0.6 
Not 
reported 
SNA and 
XNA  0.4 
S+XNA 
3.7 
SNA X+ 
2.9 
Ethiopia 
2011 
277 (208-
347) 
258(191-
335) 
Cough ≥ 2 
weeks 
Portable X-
ray machine 
Any abnormality 
in lung field or 
mediastinum, 
Culture 
positive 
S+ and/or X+ 46697 
Not 
reported 
Not 
reported 
1.7 6.4 
S-X- or S-
XNA 87.1 
S+X- or 
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including cavities, 
infiltrates, pleural 
effusion, hilar or 
mediastinal 
lymphadenopathy, 
pulmonary 
nodules, 
interstitial 
abnormalities 
suggestive or TB 
or healed TB 
S+XNA 
4.7 
Gambia 
2012 
179 (149-
231) 
175 (132-
215) 
Cough ≥ 2 
weeks, or 
cough ≤ 2 
weeks plus 
≥ 2 
symptoms 
suggestive 
of TB, or 
no cough 
but ≥3 
symptoms 
suggestive 
of TB 
Digital 
mobile X-ray 
Any abnormality 
in lung field or 
mediastinum, 
including cavities, 
infiltrates, pleural 
effusion, hilar or 
mediastinal 
lymphadenopathy, 
pulmonary 
nodules, 
interstitial 
abnormalities 
suggestive or TB 
Culture 
positive 
S+ and/or X+ 43100 
Not 
reported 
5.5 2.4 5.5 
S+XNA 
0.13 
S-XNA or 
S-X- 86.2 
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or healed TB 
Ghana 
2013 
327 (282-
347) 
Not 
reported 
Cough ≥ 2 
weeks 
Digital 
mobile X-ray 
Any abnormalities 
in lung, pleura, 
mediastinum 
Culture 
positive 
and/or Xpert 
positive with 
X+ 
S+ and/or  X+  
or XNA 
61726 86.6 1.8 1.2 7.1 
 S+XNA 
0.1 
S-XNA 3.1 
Kenya 
2015 
558 (455-
662) 
Not 
reported 
Cough ≥ 2 
weeks 
Digital 
mobile X-ray 
Any finding 
suggestive of TB 
Culture 
positive 
and/or Xpert 
positive 
S+ and/or  X+  
or XNA 
63050 84.6 4.5 2 8.2 
S-XNA 0.6 
S+XNA 
0.5 
Malawi 
2013b 
452 (312-
593) 
Not 
reported 
≥ 1 week 
of cough or 
sputum or 
blood in 
sputum or 
chest pain 
or weight 
loss or 
night 
sweat or 
fatigue or 
fever or 
shortness 
of breath 
Conventional 
radiography 
(film 
system), 
portable X-
ray 
generator 
Any lung 
abnormality 
(opacities, 
cavitation, 
fibrosis, 
calcification) 
Culture 
positive 
and/or Xpert 
positive 
S+ and/or  X+  
or XNA 
31579 88.8 7.4 1.2 2.3 
 S+XNA 
0.2 
S-XNA 
0.03 
missed 
0.2 
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Namibia 
2017 
431 (361.4-
514.3) 
Not 
reported 
Cough or 
weight loss 
or fever or 
night 
sweats 
Portable X-
ray machine 
Any abnormality 
suggestive of TB, 
read by automatic 
software and 
radiologist 
Culture 
positive 
and/or Xpert 
positive 
S+ and/or  X+  
or XNA 
29495 63.2 14 5.8 11.3 
S+XNA 
1.5 
S-XNA 4.3 
Nigeria 
2012 
524 (378-
670) 
108 (50-
186) 
cough ≥ 2 
weeks 
Mass 
miniature 
radiography 
Any abnormality 
suggestive of TB 
Smear 
positive 
and/or culture 
positive 
S+ and/or  X+  
or XNA 
44186 
Not 
reported 
Not 
reported 
1.7 5 
S-X- or S-
XNA 89.4 
S+X- or 
S+XNA 
3.9 
Rwanda 
2012 
119.3 
(78.8-
159.9) 
Not 
reported 
cough any 
duration 
Not reported 
Any abnormality 
suggestive of TB 
Culture 
positive 
S+ and/or  X+  
or XNA 
43128 88.8 4.8 1.3 4.9 
S+ XNA 
0.02 
S- XNA 
0.1 
SNA X- 
0.02 
Sudan 
2014 
183.4 
(129.6-
237.2) 
Not 
reported 
cough ≥ 2 
weeks 
Digital 
mobile X-ray 
Any lung 
abnormality, 
including pleura 
Culture 
positive 
and/or NAAT 
positive 
S+ and/or  X+  
or XNA or TB 
current 
treatment 
83202 78.2 
Not 
reported 
2.2 
Not 
reported 
S-X- or 
SNA XNA 
0.7 
SNA XNA 
0.13 
S+XNA or 
S+X- 0.8 
S-X+ or 
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SNA X+ 
11.6 
S-XNA 6.3 
Tanzania 
2012 
307 (261-
360) 
Not 
reported 
cough ≥ 2 
weeks or 
hemoptysis 
or fever ≥ 2 
weeks or 
weight loss 
or 
excessive 
sweating 
Digital 
mobile X-ray 
Any abnormalities 
in the lung field or 
mediastinum 
Culture 
positive 
S+ and/or  X+  
or XNA 
50447 87.5 6.4 1.7 3.7 
S+XNA 
0.6 
SNAX+ 
0.08 
Uganda 
2014 
401 (292-
509) 
Not 
reported 
cough ≥ 2 
weeks 
Digital 
mobile X-ray 
Any abnormalities 
in lung 
Culture 
positive 
and/or Xpert 
positive 
S+ and/or  X+  
or XNA 
41154 87.5 5.2 1.3 5.6 XNA 0.4 
Zambia 
2014 
638 (505-
774) 
Not 
reported 
cough ≥ 2 
weeks or 
fever ≥ 2 
weeks or 
chest pain 
≥ 2 weeks 
Digital 
mobile X-ray 
Any lung 
abnormality 
excluding heart 
and bone 
abnormality 
Culture 
positive 
and/or Xpert 
positive 
S+ and/or  X+  
or XNA 
46099 84.2 6.3 3.6 4.9 
S+XNA 
0.09 
S-XNA 1.2 
Zimbabwe 
2014 
317.1 
(250.5-
Not 
reported 
Any 
symptom 
Digital 
mobile X-ray 
Any abnormalities 
in lung 
Culture 
positive 
S+ and/or  X+  
or XNA 
33736 82.7 3.4 1.9 8.3 
 S-XNA 
3.5 
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383.8) and/or Xpert 
positive 
S+XNA 
0.1 
"other" 
0.03 
 
NA= not applicable, used when results for symptom (SNA) or X-ray screening (XNA) were not available; S= symptoms; X= X-ray 
A list of references for included prevalence surveys is available in Supplementary Material as Appendix 1. 
aSurveys from China were excluded from the analysis because results active pulmonary cases, of which the proportion of bacteriologically negative clinically 
diagnosed cases is unknown 
bMalawi 2013: Results were excluded from the analysis because the quality of images observed in some clusters was sub-standard, and could not be 
compared with results from other countries[12] 
c Some data was not obtainable from Thailand 2012, because the only version of the survey report available was in Thai 
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Table 2. Subnational surveys in India 
Survey 
Prevalence of TB (95%CI) /100 
000 population 
Bacteriological confirmation test 
Criteria for eligibility for 
bacteriological 
examination 
S-X+ cases 
(%) 
S- cases 
(%) 
Tamil Nadu (India) 1999  605 One culture positive sample S+ and/or X+ 46.3 46.3 
Tamil Nadu (India) 2001 454 Culture positive 
S+ and/or X+ and all 
known TB cases 
33.7 36 
Tamil Nadu (India) 2004  309 Culture positive 
S+ and/or X+ and all 
known TB cases 
36.4 39.1 
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Tamil Nadu (India) 2006  388 Culture positive 
S+ and/or X+ and all 
known TB cases 
34.9 39.2 
Tamil Nadu (India) 2010  259 Culture positive 
S+ and/or X+ and all 
known TB cases 
32.9 55 
 
A list of references for included prevalence surveys is available in Supplementary Material as Appendix 1. 
S= symptoms; X= X-ray 
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Table 3. Characteristics of bacteriologically confirmed cases 
Survey 
S-X+ cases 
(%) 
S- cases 
(%) 
S+ cases  
(%) 
X+ cases 
(%) 
S+X- cases 
(%) 
S+X+ cases  
(%) 
Proportion 
negative on 
ANY 
symptom  
among 
cases 
(%) 
Proportion of 
males among all 
bacteriologically 
confirmed cases  
(%) 
HIV prevalence 
among all 
bacteriologically 
confirmed cases 
(%) 
Percentage 
of cases 
found 
already in 
TB care 
(%) 
Bacteriologically 
confirmed 
notification rate 
(n/100,000) 
Prevalence 
to 
notification 
ratio 
Bangladesh 
2015 
61.9 61.9 38.1 90.3 9.7 36 
Not 
reported 
72.3 Not measured 1.8 101.7 2.8 
Cambodia 
2002 
60.9 60.9 39.1 95.6 4.4 34.7 15.9 60 Not measured 4.2 222.9 2.0 
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Cambodia 
2011 
69.4 70.4 29.1 95.6 3.5 25.6 10.2 59.9 Not measured 2 161.4 1.7 
China 2000a 
Not 
reported 
12.1 87.9 49.5 
Not 
reported 
Not 
reported 
Not 
reported 
70.4 Not reported 
Not 
reported 
Not reported 
Not 
available 
China 2010a 
Not 
reported 
43.1 56.9 
Not 
reported 
Not 
reported 
Not 
reported 
Not 
reported 
69.9 Not reported 
Not 
reported 
38.7 1.7 
DPR Korea 
2016 
42.9 42.9 57 97.9 0.7 55 
Not 
reported 
69.7 Not measured 31.2 482.1 1.2 
Indonesia 
2014 
42.5 42.5 57.5 94.1 4.9 51.6 
Not 
reported 
65.5 Not measured 4.5 113.3 2.3 
Lao PDR 
2011 
50.2 50.2 49.8 97 2.9 46.8 
Not 
reported 
66.2 Not measured 2.5 80.4 3.5 
Mongolia 
2015 
77.8 79.4 20.6 96 2.5 18.1 42.7 64.5 Not measured 4.4 83.2 2.5 
Myanmar 
2009 
Not 
reported 
78.8 19.7 95.2 
Not 
reported 
Not 
reported 
38.2 66.2 Not measured 3.5 114.4 2.1 
Philippines 
2016 
63.9 67.8 32.2 92.2 1.7 28.3 26 69 Not measured 6.4 142.2 3.1 
Thailand 
2012c 
66.2 66.2 33.8 95.8 4.2 29.6 
Not 
obtainable 
Not obtainable Not obtainable 
Not 
obtainable 
56.4 1.8 
Vietnam 
2007 
67.3 73.6 26.4 85.1 8.5 17.8 
Not 
reported 
78.8 Not measured 0.07 85.2 2.3 
Ethiopia 
2011 
48.2 48.2 51.8 89 10.9 40.9 
Not 
reported 
55.3 8.00 2.7 91.0 1.2 
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Gambia 
2012 
36.6 38. 62 81.7 15.5 45 
Not 
reported 
62 Not measured 5 145.3 0.6 
Ghana 2013 
Not 
reported 
59 41 75.2 
not 
reported 
not 
reported 
Not 
reported 
50 Not reported 5 45.2 2.5 
Kenya 2015 50.5 51.8 40.2 88.2 10.5 38 
Not 
reported 
62 13.4 4.9 158.2 3.5 
Malawi 
2013b 
30.3 30.3 69.7 49.2 50.76 18.9 
Not 
reported 
47.7 16.7 4.5 86.8 2.5 
Namibia 
2017 
Not 
reported 
51.3 48.7 95 
not 
reported 
not 
reported 
Not 
reported 
60 15.1 4.2 551.9 0.8 
Nigeria 2012 
Not 
reported 
36.1 63.9 89 
not 
reported 
not 
reported 
22.9 67.7 Not measured 0.2 55 5.8 
Rwanda 
2012 
50 50 50 79.6 20.4 27.8 
Not 
reported 
73.7 3.7 5.3 56.1 1.3 
Sudan 2014 40 40 45.1 78 7.1 38 
Not 
reported 
Not reported Not measured 7.1 25 3.5 
Tanzania 
2012 
not 
reported 
36.7 63.2 73.5 
not 
reported 
not 
reported 
Not 
reported 
60 5.9 
Not 
reported 
92.8 3 
Uganda 
2014 
50.6 50.6 49.4 88.7 10 38.1 
Not 
reported 
75 26.9 10 141.8 2.8 
Zambia 
2014 
39 39 61 83 17 44 
Not 
reported 
66.7 13.2 2.6 159.2 2.0 
Zimbabwe 
2014 
Not 
reported 
63.55 36 86 
not 
reported 
not 
reported 
Not 
reported 
54.2 Not reported 
Not 
reported 
137.9 2.5 
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A list of references for included prevalence surveys is available in Supplementary Material as Appendix 1. 
S= symptoms, X= X-ray 
aSurveys from China were excluded from the analysis because results active pulmonary cases, of which the proportion of bacteriologically negative clinically 
diagnosed cases is unknown 
bMalawi 2013: Results were excluded from our study because the quality of images observed in some clusters was sub-standard, and could not be 
compared with results from other countries[12] 
cSome data was not obtainable from Thailand 2012, because the only version of the survey report available was in Thai 
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Table 4. Survey level associations with the proportion of prevalent TB that is subclinical 
Variable 
(n observations) 
Change in proportion of subclinical TB (95% CI) p-value 
Continent (24) 
   Africa 
   Asia 
 
Reference 
15.2% (5.6 – 24.8) 
 
0.003 
HIV prevalence in country (24) 
Continuous variable -0.7% (-2.0 – 0.7) 0.34 
HIV prevalence in country (24) 
Below 1% 
1-2% 
≥2% 
 
Reference 
-5.4% (-18.9 – 8.1) 
-10.9% (-24.4 – 2.7) 
 
 
0.41 
0.11 
Symptom screening (24) 
Any symptom 
Cough ≥ 2 weeks 
Cough ≥ 2 weeks and/or other symptoms 
 
Reference 
-5.0% (-22.1 – 12.1) 
-10.1% (-26.8 – 6.5)  
 
 
0.55 
0.22 
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TB Prevalence (23) 0.01% (-0.001 – 0.003) 0.32 
Patient Diagnostic Rate, 
 average in the previous 5 years (22) -8.7% (-29.8 – 12.4) 0.4 
Proportion of male among the cases (21) 0.1% (-0.8 – 1.0) 0.79 
Results from univariate meta-regression. 
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FIGURES  
Figure 1: TB prevalence surveys selection flowchart 
 
Figure 2: Proportion of subclinical disease in prevalence surveys  
 
Figure 2 shows the proportion of all prevalent cases that was subclinical (bars – left side Y-axis) by 
the adult crude prevalence of bacteriologically-confirmed TB found in that survey (crosses – right 
side Y-axis). The first three bars show the median (bar) and interquartile range (error bars) for values 
found in surveys in Africa, Asia and overall.  
Sub= subnational surveys 
 
Figure 3: Screening modality for bacteriologically-confirmed cases  
 
Figure 3 shows the proportion of bacteriologically-confirmed cases in prevalence surveys that 
screened positive on X-ray (Y-axis), or on symptom-screen only (X-axis). Raw data is available in 
Table 3. 
Note: The Vietnam 2007 and Sudan 2014 surveys did not report symptom screening and X-ray 
results for TB cases who were under treatment or had history of treatment within 2 years, but did 
receive bacteriological examination; In the Philippines 2016 survey, 5% of bacteriologically-
confirmed cases were exempted from X-ray (see Table 1). 
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Figure 4: Population screening results 
 
Figure 4 shows the proportion of population included in prevalence surveys that screened positive 
on X-ray (S-X+), symptom screen (S+X-), both (S+X+) or neither (S-X-).  
 
Figure 5: Model representation of the natural history of Mycobacterium tuberculosis infection and 
tuberculosis disease 
 
Figure 5 shows different states of M.tb infection (green) and TB disease (purple) and that infected 
individuals can progress and regress across the spectrum.  
Naive = never been infected; Infected = viable M.tb infection, with potential to progress to disease; 
Self-cleared = individual has cleared the M.tb infection, and cannot progress to disease without re-
infection (dashed arrows);  Minimal disease = pathological changes caused by M.tb, but 
bacteriologically negative; Incipient disease= transition from minimal to subclinical disease; 
Subclinical disease = bacteriologically-confirmed, negative at symptom screening; Clinical disease = 
bacteriologically confirmed and symptomatic;  
Incipient disease (gray circle) = transition from minimal to subclinical disease; 
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Figure_2 
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Figure_3 
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Figure_4 
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Figure_5 
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